Latest news
The approval of Zulresso and Zurzuvae marks a milestone in postpartum depression treatment, yet experts say diagnosis and access barriers still limit care. The field has evolved from dismissing PPD to recognizing it, but underdiagnosis, lack of trained providers, and socioeconomic factors continue to hinder progress. Sage Therapeutics' drugs face challenges including high costs, logistical requirements, and a sparse pipeline. While the new treatments offer faster relief, broader cultural and systemic changes are needed to improve maternal mental health.
Although two drugs specifically targeting postpartum depression (PPD) have been approved and launched in the United States, their clinical application has progressed slowly due to factors such as insufficient social awareness, late establishment of diagnostic criteria, and poor treatment accessibility. This article reviews the history of PPD from being overlooked to gaining formal diagnostic status, analyzes the limitations of existing treatment options, and explores the practical challenges in promoting the new drugs.
After two decades of retreat, psychiatry drugs are back in the spotlight with Bristol Myers Squibb's $14 billion acquisition of Karuna Therapeutics and AbbVie's $9 billion proposal for Cerevel. Karuna's KarXT, a novel antipsychotic, could be approved by September, marking the first new mechanism in decades. While the deals and promising pipeline excite researchers, they caution that high failure rates, complex brain biology, and unreliable animal models still pose significant hurdles. Experts debate whether big pharma will commit long-term or leave innovation to smaller biotechs.
Women's health enterprises have long faced the dilemma of insufficient R&D investment, but recent policy support and market attention are driving industry transformation. This article analyzes investment barriers, regulatory challenges, and growth potential.
